MOTS-c: the compound on this map that never reaches the pituitary

Start here

Almost every peptide has its instructions written in the DNA held in the cell's nucleus. MOTS-c does not. Its instructions sit inside the mitochondria — the small compartments that produce most of a cell's energy — which carry a tiny genome of their own.

What MOTS-c does is not release a hormone. It interferes with a chemical assembly line called the folate cycle, and the by-product of that interference switches on AMPK, a sensor that tells a cell it is short of energy and should start burning fuel rather than storing it. Skeletal muscle is where most of this happens. Under stress, the peptide also travels into the nucleus and changes which genes are switched on there, which is a genuinely unusual thing for a mitochondrial product to do.

None of that involves the pituitary, growth hormone or IGF-1. MOTS-c appears on this map because retailers file it with growth-hormone peptides, and the point of a map is to show where things actually are.

What it is

MOTS-c is a 16-amino-acid peptide, sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame inside the mitochondrial 12S ribosomal RNA gene, MT-RNR1. It is highly conserved across mammalian species and belongs to the class of mitochondrial-derived peptides. The modern reference frame for its biology — its encoding within MT-RNR1, its AMPK and folate-cycle mechanism, its nuclear translocation, its inducibility by exercise, and its roles across metabolic, stress-adaptive and aging pathways — is set out in a comprehensive 2023 review ^[19].

It is not approved by the FDA for any use, and it is sold only for laboratory research. There is no approved indication, no approved formulation and no established dosing. There is also no published, measured human half-life, bioavailability or dose-response, which is a more specific gap than it sounds: rodent work uses milligram-per-kilogram exposures that cannot be extrapolated to people, and no human pharmacokinetic study exists to bridge them.

It is treated as a prohibited peptide in elite sport, covered by anti-doping authorities under hormone-and-metabolic-modulator categories.

How it works

The best-characterised action is inhibition of the folate cycle and of de novo purine biosynthesis. That inhibition raises AICAR, an endogenous activator of AMP-activated protein kinase, and the resulting AMPK activation improves glucose handling and insulin sensitivity — principally in skeletal muscle.

Two further mechanisms complete the picture, and both are unusual. First, retrograde signalling: under metabolic stress MOTS-c translocates from the mitochondrion into the nucleus and regulates nuclear gene expression in an AMPK-dependent manner, including antioxidant-response-element genes through interaction with NRF2. That was the first demonstrated instance of a mitochondrially encoded peptide signalling back to the nuclear genome ^[21]. Second, a direct molecular target: a 2024 study showed that MOTS-c binds and activates casein kinase 2 in cell-free systems, and that tissue-specific modulation of CK2 — activation in muscle, suppression in fat — underlies its effects on muscle glucose uptake and on the prevention of atrophy ^[17].

Set against the other three compounds on this desk, the contrast is total. Sermorelin and CJC-1295 act on a G-protein-coupled receptor on a pituitary cell. Ipamorelin acts on a different G-protein-coupled receptor on the same pituitary cell. MOTS-c acts on an intracellular metabolic pathway in muscle and, under stress, on transcription in the nucleus. There is no receptor in common, no cell type in common, and no shared downstream axis. The only thing the four share is a retail category.

What the research shows

Exercise mimicry is the central animal result. Exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation, and administered MOTS-c significantly enhanced physical performance in young, middle-aged and old mice — the finding that positions it as an exercise-mimetic regulator of healthspan ^[20]. It is also the finding most often compressed into a product claim, and it is a mouse result.

The direct target is recent and mechanistic. The identification of casein kinase 2 as a directly bound and activated target, with opposite tissue-specific modulation in muscle and fat driving glucose uptake and atrophy prevention, is 2024 work in cell-free and cellular systems ^[17]. It sharpens the mechanism considerably. It does not move the compound closer to a clinical outcome.

Retrograde signalling is established. The mitochondrion-to-nucleus translocation and AMPK-dependent regulation of NRF2-linked antioxidant-response genes under metabolic stress is a demonstrated phenomenon and the reason MOTS-c is discussed in aging biology at all ^[21].

The strongest human data are observational, not interventional. In a prospective multicentre cohort of 94 chronic haemodialysis patients followed for a median of 26.5 months, circulating MOTS-c was independently associated with a composite of all-cause mortality and non-fatal cardiovascular events and improved the discrimination of the risk model ^[18]. That is among the strongest human clinical-association data available for the peptide — and it measures the body's own MOTS-c as a biomarker in a specific patient population. It says nothing about administering the peptide to anyone.

What does not exist. No human efficacy trial of exogenous MOTS-c, for any indication, at any duration. Every claim about administered MOTS-c improving metabolism, performance or aging traces back to cell or animal work. Several human biomarker studies are small or preliminary and some mechanistic effects await independent replication. And the effect is not uniform across people: a pro-diabetogenic MOTS-c mitochondrial-DNA variant and ancestry-dependent exercise responses have both been described, which means population-level generalisation is unsafe even for the endogenous peptide.

Reported effects, cautions and safety

This page cannot report community experience the way the three pituitary-facing pages do. The audited corpus behind this site records no catalogued set of user-reported effects for MOTS-c and no compound-specific safety-caution set, and this desk does not manufacture either. An absent evidence block is reported as absent.

What the record does support is a set of documented concerns, and they are unusually clean-edged for a compound with this much consumer interest:

• No human interventional evidence at all. Every efficacy claim originates in cells or in rodents ^[17][19][20]. The human literature is observational biomarker work ^[18].
• No validated human pharmacokinetics. No published measured half-life, bioavailability or dose-response in people. Rodent exposures are milligram-per-kilogram and are not extrapolable. This is the reason no schedule of any kind appears on this site for MOTS-c: there is no human quantity in the literature to describe, let alone to recommend.
• Research-chemical supply. Not approved by the FDA for any use and sold only for laboratory research; purity, identity and sterility vary by supplier and are not regulated as pharmaceutical attributes.
• Genotype and ancestry interactions. A pro-diabetogenic mitochondrial variant and ancestry-dependent exercise responses indicate that effects are not uniform across populations — a caution that applies to interpreting studies as much as to anything else.
• Replication is incomplete. Some human biomarker studies are small or single-lab, and some mechanistic effects have not yet been independently reproduced.
• Prohibited in elite sport, with sanctions for athlete use.

The gap between consumer interest in this peptide — fat loss, longevity, performance — and the strength of its clinical evidence is the widest on this desk. Naming that gap precisely is the reason it has a page here.

Where it sits on the map

MOTS-c sits off the axis, and that is its position rather than a caveat on it. Nothing about its mechanism runs through GHRHR, GHS-R1a, the somatotroph, growth hormone or IGF-1. It belongs to a different biology entirely: mitochondrial-derived signalling, AMPK, and a transcriptional response to metabolic stress.

It earns a place on a growth-hormone-axis map for two reasons. It is sold and discussed alongside the secretagogues, so a reader arriving from that context needs the correction. And the overlap that does exist is at the level of outcomes people care about — body composition, energy metabolism, performance in aging — reached by a route that shares no molecular step with the other three. Two compounds that produce similar-sounding claims through unrelated mechanisms are exactly what a precision map is for.